Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 297935
Under a license from Licensor, Licensee has right to use the XpressCFÂ® and XpressCF+â„¢ platforms to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases.
XpressCFÂ® – integrated cell-free protein synthesis platform
XpressCF+â„¢ – site-specific conjugation platform
Both of these platforms allow to rapidly and precisely create optimally designed, next-generation protein therapeutics candidates.
The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates.
IPSCIO Record ID: 305790
Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.
The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.
XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.
The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.
Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.
IPSCIO Record ID: 307594
The companies will partner to develop Licensorâ€™s next-generation bispecific antibody programs, epcoritamab (DuoBodyÂ®-CD3xCD20), DuoHexaBodyÂ®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensorâ€™s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licenseeâ€™s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensorâ€™s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licenseeâ€™s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBodyÂ® platform for generation of bispecific antibodies, the HexaBodyÂ® platform, which creates effector function enhanced antibodies, the HexElectÂ® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBodyÂ® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
IPSCIO Record ID: 307944
Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.
IPSCIO Record ID: 305251
Premas vaccine platform is certain patent applications, know-how and other proprietary information related to a vaccine platform that involves genetically engineered and modified yeast, Saccharomyces cerevisiae, which along with certain proprietary expression vectors and optimized genes developed to be used with the above strain, and, has been shown to be useful in the expression of more than thirty type 1 endoplasmic reticulum associated proteins.
IPSCIO Record ID: 304223
The Inventions and Technologies licensed relate to the ABBIE patent estate that includes patent families. One such family is titled â€œNovel Nanoparticleâ€“Based Vaccine Targeting Cancer/Testis Antigens (CTA) and itsâ€™ Use in Solid and Hematological Malignanciesâ€. The use and methods for a vaccine composition comprising of particles comprising nanoparticles, microparticles or a mixture thereof.
ABBIE is a non-viral gene editing mechanism to insert the target DNA template information into the T cell genome at a precise, predetermined locus. ABBIE allows the creation of the plasmid (â€œglueâ€) that goes through the membrane to the nucleus and inserts the genome template into the T cells so that they could express the CAR T protein and possibly other accessory proteins while possibly eliminating unwanted inhibitory proteins.
The license granted is for the inventions and technologies for the use of oral vaccines for any diseases, including, without limitation, any form of cancer.
IPSCIO Record ID: 28795
Licensor grants a nonexclusive research and development license for Licensee to practice the use of Licensor' s cancer vaccines identified in the Licensor Patents and the antigens which they contain, to the extent that Licensor has a Valid Claim on any antigens included in any or all vaccines.
Biological Material shall mean human blood and lymphocytes obtained from patients enrolled in the Participating Licensor Clinical Trials.
The patents include
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthesis of glycoconjugates of the globo-h epitope and uses thereof;
Synthesis Of The Breast Tumor-Associated Antigen Defined By Monoclonal Antibody MBR-1 And Uses Thereof;
Polyvalent Conjugate Vaccine for Cancer; and,
Optimal Polyvalent Vaccine for Cancer.